(Q34590270)

3 August 2017

title

International consensus statement on the use of disease-modifying agents in multiple sclerosis (English)

1 reference

3 August 2017

0 references

M S Freedman

1

1 reference

3 August 2017

L D Blumhardt

2

1 reference

3 August 2017

B Brochet

3

1 reference

3 August 2017

G Comi

4

1 reference

3 August 2017

J H Noseworthy

5

1 reference

3 August 2017

M Sandberg-Wollheim

6

1 reference

3 August 2017

Sørensen P Soelberg

7

1 reference

3 August 2017

Paris Workshop Group

8

1 reference

3 August 2017

publication date

1 February 2002

1 reference

Multiple Sclerosis Journal

3 August 2017

published in

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

19-23

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Axonal damage in acute multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS769OA

10.1191/1352458502MS769OA

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n3nw6djcobblfbazyt7i6ho42i

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_n3nw6djcobblfbazyt7i6ho42i

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n3nw6djcobblfbazyt7i6ho42i

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/n3nw6djcobblfbazyt7i6ho42i

1 reference